Businello, Gianluca
Angerilli, Valentina
Lonardi, Sara
Bergamo, Francesca
Valmasoni, Michele
Farinati, Fabio
Savarino, Edoardo
Spolverato, Gaya
Fassan, Matteo http://orcid.org/0000-0001-6515-5482
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (22759)
Regione del Veneto (NET-2016–02363853)
Università degli Studi di Padova
Article History
Received: 18 March 2022
Accepted: 5 July 2022
First Online: 14 July 2022
Declarations
:
: SL reports personal fees (as speaker bureau or advisor) from Amgen, Merck Serono, Lilly, Astra Zeneca, Incyte, Daiichi-Sankyo, Bristol-Myers Squibb, Servier, MSD, Roche, Pierre-Fabre, GSK, and received research grants from Amgen, Merck Serono, Bayer, Roche, Lilly, Astra Zeneca, Bristol-Myers Squibb, unrelated to the current work. MF reports personal fees (as speaker bureau or advisor) from Roche, MSD, GSK, Astellas Pharma, Diaceutics and received research grants from Astellas Pharma, QED therapeutics, and macrophage pharma, unrelated to the current work. ES has served as a speaker for Abbvie, AGPharma, Alfasigma, EG Stada Group, Fresenius Kabi, Grifols, Janssen, Innovamedica, Malesci, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Unifarco, served as a consultant for Alfasigma, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Diadema Farmaceutici, Falk, Fresenius Kabi, Janssen, Merck & Co, Reckitt Benckiser, Regeneron, Sanofi, Shire, SILA, Sofar, Synformulas GmbH, Takeda, Unifarco and he received research support from Reckitt Benckiser, SILA, Sofar, Unifarco, unrelated to the current work.